These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 34132654)
1. A Review of the Role of Type 2 Diabetes Mellitus and Sodium-Glucose Cotransporter-1 Inhibitors in Heart Failure With Preserved Ejection Fraction. Palaguachi GI; Frishman W Cardiol Rev; 2022 Sep-Oct 01; 30(5):274-278. PubMed ID: 34132654 [TBL] [Abstract][Full Text] [Related]
2. Sodium-glucose cotransporter 2 inhibitors represent a paradigm shift in the prevention of heart failure in type 2 diabetes patients. Kashiwagi A; Araki S; Maegawa H J Diabetes Investig; 2021 Jan; 12(1):6-20. PubMed ID: 32563214 [TBL] [Abstract][Full Text] [Related]
3. Use of Sodium-Glucose Cotransporter-2 Inhibitors in Clinical Practice for Heart Failure Prevention and Treatment: Beyond Type 2 Diabetes. A Narrative Review. Rao S Adv Ther; 2022 Feb; 39(2):845-861. PubMed ID: 34881413 [TBL] [Abstract][Full Text] [Related]
4. The Role of Sodium-Glucose Cotransporter-2 Inhibitors in Patients With Heart Failure, Regardless of Diabetes Status: Focus on Cardiovascular Disease. Ferrari F; Martins VM; Scheffel RS; da Silveira AD; Motta MT; Moriguchi EH; Santos RD; Stein R Ann Pharmacother; 2021 Oct; 55(10):1267-1275. PubMed ID: 33401940 [TBL] [Abstract][Full Text] [Related]
5. Clinical Benefits of Sodium-Glucose Cotransporter 2 Inhibitors and the Mechanisms Underlying Their Cardiovascular Effects. Kubota Y; Shimizu W JACC Asia; 2022 Jun; 2(3):287-293. PubMed ID: 36338417 [TBL] [Abstract][Full Text] [Related]
7. Potential Therapeutic Benefits of Sodium-Glucose Cotransporter 2 Inhibitors in the Context of Ischemic Heart Failure: A State-of-the-Art Review. Gitto M; Vrachatis DA; Condorelli G; Papathanasiou K; Reimers B; Deftereos S; Stefanini GG Cardiovasc Hematol Agents Med Chem; 2022; 20(2):90-102. PubMed ID: 34370645 [TBL] [Abstract][Full Text] [Related]
8. Sodium-Glucose Cotransporter 2 Inhibitors in Heart Failure. Shah KS; Fang JC Annu Rev Pharmacol Toxicol; 2022 Jan; 62():109-120. PubMed ID: 34516288 [TBL] [Abstract][Full Text] [Related]
9. SGLT-2 Inhibitors for Patients with Heart Failure: What Have We Learned Recently? Al Rifai M; Newby LK; Nair AP; Misra A; Rogers JG; Fedson S; Virani SS Curr Atheroscler Rep; 2022 Aug; 24(8):627-634. PubMed ID: 35653033 [TBL] [Abstract][Full Text] [Related]
10. Sodium-glucose cotransporter 2 inhibitors in heart failure with preserved ejection fraction: A protocol for meta-analysis. Fukuta H; Hagiwara H; Kamiya T Medicine (Baltimore); 2021 Dec; 100(51):e28448. PubMed ID: 34941199 [TBL] [Abstract][Full Text] [Related]
11. The current role of sodium-glucose cotransporter 2 inhibitors in type 2 diabetes mellitus management. Xu B; Li S; Kang B; Zhou J Cardiovasc Diabetol; 2022 May; 21(1):83. PubMed ID: 35614469 [TBL] [Abstract][Full Text] [Related]
12. The effects of sodium-glucose cotransporter 2 inhibitors on left ventricular function: current evidence and future directions. Lan NSR; Fegan PG; Yeap BB; Dwivedi G ESC Heart Fail; 2019 Oct; 6(5):927-935. PubMed ID: 31400090 [TBL] [Abstract][Full Text] [Related]
13. When and How to Use Sodium-Glucose Cotransporter 2 Inhibitors in Patients With Heart Failure With Reduced Ejection Fraction or Chronic Kidney Disease. O'Meara E; Verma S Can J Cardiol; 2021 Apr; 37(4):669-673. PubMed ID: 33450364 [TBL] [Abstract][Full Text] [Related]
16. Heart Failure With Type 2 Diabetes Mellitus: Association Between Antihyperglycemic Agents, Glycemic Control, and Ejection Fraction. Lin SN; Phang KK; Toh SH; Chee KH; Zaman Huri H Front Endocrinol (Lausanne); 2020; 11():448. PubMed ID: 32754118 [No Abstract] [Full Text] [Related]
17. Sodium-Glucose Cotransporter-2 inhibitors are potential therapeutic agents for treatment of non-diabetic heart failure patients. Nakagawa Y; Kuwahara K J Cardiol; 2020 Aug; 76(2):123-131. PubMed ID: 32340780 [TBL] [Abstract][Full Text] [Related]
18. Impact of Dapagliflozin on the Left Ventricular Diastolic Function in Diabetic Patients with Heart Failure Complicating Cardiovascular Risk Factors. Soga F; Tanaka H; Tatsumi K; Mochizuki Y; Sano H; Toki H; Matsumoto K; Shite J; Takaoka H; Doi T; Hirata KI Intern Med; 2021; 60(15):2367-2374. PubMed ID: 34334588 [TBL] [Abstract][Full Text] [Related]
19. Effect of sodium-glucose cotransporter 2 inhibitors on cardiac structure and function in type 2 diabetes mellitus patients with or without chronic heart failure: a meta-analysis. Yu YW; Zhao XM; Wang YH; Zhou Q; Huang Y; Zhai M; Zhang J Cardiovasc Diabetol; 2021 Jan; 20(1):25. PubMed ID: 33494751 [TBL] [Abstract][Full Text] [Related]
20. Clinical potential relevance of metabolic properties of SGLT2 inhibitors in patients with heart failure. Galli M; D'Amario D; Sofia C; Vaccarella M; Crea F; Aspromonte N Expert Opin Drug Metab Toxicol; 2018 Dec; 14(12):1273-1285. PubMed ID: 30472914 [No Abstract] [Full Text] [Related] [Next] [New Search]